Additional Paid in Capital of Enlivex Therapeutics Ltd. from 31 Dec 2013 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Enlivex Therapeutics Ltd. quarterly Additional Paid in Capital in USD history and change rate from 31 Dec 2013 to 30 Jun 2025.
  • Enlivex Therapeutics Ltd. Additional Paid in Capital for the quarter ending 30 Jun 2025 was $147,672,000.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $147,672,000 30 Jun 2025 6-K 29 Aug 2025 2025 Q2
Q4 2024 $146,910,000 +$7,971,000 +5.7% 31 Dec 2024 6-K 29 Aug 2025 2025 Q2
Q4 2023 $138,939,000 +$2,291,000 +1.7% 31 Dec 2023 20-F 30 Apr 2025 2024 FY
Q2 2023 $138,133,000 +$2,758,000 +2% 30 Jun 2023 6-K 01 Sep 2023 2023 Q2
Q4 2022 $136,648,000 +$2,852,000 +2.1% 31 Dec 2022 20-F 30 Apr 2024 2023 FY
Q2 2022 $135,375,000 +$3,712,000 +2.8% 30 Jun 2022 6-K 22 Aug 2022 2022 Q2
Q4 2021 $133,796,000 +$63,435,000 +90% 31 Dec 2021 20-F 10 Apr 2023 2022 FY
Q2 2021 $131,663,000 +$72,048,000 +121% 30 Jun 2021 6-K 06 Aug 2021 2021 Q2
Q4 2020 $70,361,000 +$33,257,000 +90% 31 Dec 2020 20-F 29 Apr 2022 2021 FY
Q2 2020 $59,615,000 30 Jun 2020 6-K/A 13 Oct 2020 2020 Q2
Q4 2019 $37,104,000 +$9,778,000 +36% 31 Dec 2019 20-F 30 Apr 2021 2020 FY
Q4 2018 $27,326,000 -$21,545,000 -44% 31 Dec 2018 20-F 30 Apr 2020 2019 FY
Q4 2017 $48,871,000 +$408,000 +0.84% 31 Dec 2017 20-F/A 23 Jan 2020 2018 FY
Q4 2016 $48,463,000 +$6,783,000 +16% 31 Dec 2016 20-F 23 Apr 2018 2017 FY
Q4 2015 $41,680,000 +$2,623,000 +6.7% 31 Dec 2015 20-F 24 Feb 2017 2016 FY
Q4 2014 $39,057,000 +$37,506,000 +2418% 31 Dec 2014 20-F 29 Mar 2016 2015 FY
Q4 2013 $1,551,000 31 Dec 2013 20-F 31 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.